Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30659611,Tmax,"DHE plasma levels following INP104 1.45 mg administration reached 93% of Cmax by 20 minutes and were comparable to IV DHE 1.0 mg by 30 minutes (1219 ng/mL for INP104 vs 1224 ng/mL for IV DHE), which was the Tmax for INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[ng] / [ml],1219,19228,DB00320,Dihydroergotamine
,30659611,Tmax,"DHE plasma levels following INP104 1.45 mg administration reached 93% of Cmax by 20 minutes and were comparable to IV DHE 1.0 mg by 30 minutes (1219 ng/mL for INP104 vs 1224 ng/mL for IV DHE), which was the Tmax for INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[ng] / [ml],1224,19229,DB00320,Dihydroergotamine
,30659611,Cmax,"In comparison, the Cmax for Migranal was 299.6 pg/mL (approximately 4-fold less than INP104) and occurred at 47 minutes, 17 minutes later than INP104.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[pg] / [ml],299.6,19230,DB00320,Dihydroergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],6275,19231,DB00320,Dihydroergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],7490,19232,DB00320,Dihydroergotamine
,30659611,AUC0-inf,"Plasma DHE AUC0-inf were 6275, 7490, and 2199 h*pg/mL for INP104, IV DHE, and Migranal, respectively.","STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30659611/),[h·pg] / [ml],2199,19233,DB00320,Dihydroergotamine
,403149,invasion half-life,The mean invasion half-life was 0.5 hours (range 0.32-1.12 hours).,Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,0.5,20609,DB00320,Dihydroergotamine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,1.4-6.2,20610,DB00320,Dihydroergotamine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,13 to 50,20611,DB00320,Dihydroergotamine
,1653135,Bioavailability,Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),%,100,23503,DB00320,Dihydroergotamine
,1653135,Bioavailability,Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),%,14,23504,DB00320,Dihydroergotamine
,1653135,plasma half-lives,The plasma half-lives of sumatriptan and the metabolite were about 2 h.,"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653135/),h,2,23505,DB00320,Dihydroergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,25,23739,DB00320,Dihydroergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,19,23740,DB00320,Dihydroergotamine
,10638398,relative bioavailabilities,"The relative bioavailabilities of the DHEM/RAMEB nasal spray, the DHEM/RAMEB nasal powder and the commercially available DHEM nasal spray were 25%, 19% and 21%, respectively, in comparison with i.m. administration.",Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,21,23741,DB00320,Dihydroergotamine
,10638398,relative bioavailability,The relative bioavailability after oral administration was 8%.,Bioavailability of intranasal formulations of dihydroergotamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638398/),%,8,23742,DB00320,Dihydroergotamine
,18534051,AUC(0-36),"Among 19 subjects, geometric mean AUC(0-36) was 6754 pg.h/mL and geometric mean AUC(0-inf) was 7483 pg.h/mL.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[h·pg] / [ml],6754,48230,DB00320,Dihydroergotamine
,18534051,AUC(0-inf),"Among 19 subjects, geometric mean AUC(0-36) was 6754 pg.h/mL and geometric mean AUC(0-inf) was 7483 pg.h/mL.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[h·pg] / [ml],7483,48231,DB00320,Dihydroergotamine
,18534051,t(max),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),min,9.6,48232,DB00320,Dihydroergotamine
,18534051,C(max),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),[pg] / [ml],3174,48233,DB00320,Dihydroergotamine
,18534051,t((1/2)),"Geometric mean t(max) was 9.6 min, geometric mean C(max) was 3174 pg/mL, and geometric mean t((1/2)) was 9.5 h.","Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534051/),h,9.5,48234,DB00320,Dihydroergotamine
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00320,Dihydroergotamine
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00320,Dihydroergotamine
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00320,Dihydroergotamine
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00320,Dihydroergotamine
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00320,Dihydroergotamine
,6714270,"t 1/2,beta","The disappearance of radioactivity from blood was biphasic, with t 1/2,alpha and t 1/2,beta values of 2.9 and 16.9 h, respectively, in man and 2.9 and 14.7 h, respectively, in the rabbit.",Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),h,16.9,57905,DB00320,Dihydroergotamine
,6714270,"t 1/2,beta","The disappearance of radioactivity from blood was biphasic, with t 1/2,alpha and t 1/2,beta values of 2.9 and 16.9 h, respectively, in man and 2.9 and 14.7 h, respectively, in the rabbit.",Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),h,14.7,57906,DB00320,Dihydroergotamine
,6714270,Apparent volumes of distribution,Apparent volumes of distribution were 18.9 Liter/kg in man and 30.4 Liter/kg in the rabbit.,Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),[l] / [kg],18.9,57907,DB00320,Dihydroergotamine
,6714270,Apparent volumes of distribution,Apparent volumes of distribution were 18.9 Liter/kg in man and 30.4 Liter/kg in the rabbit.,Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714270/),[l] / [kg],30.4,57908,DB00320,Dihydroergotamine
,7368942,infusion time,"The pharmacokinetics of dihydroergotamine (DHE) was studied in 6 beagles after a single 2.0 mg intravenous dose and after a continuous intravenous infusion (dose 2.0 mg, infusion time 51 min.=2.8-3.5 micrograms/min./kg).",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,51,59077,DB00320,Dihydroergotamine
,7368942,alpha-phase T1/2,The mean alpha-phase T1/2 was 0.92 min.,The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,0.92,59078,DB00320,Dihydroergotamine
,7368942,beta-phase T1/2,"and 5.93 min., the mean beta-phase T1/2 was 104.42 min.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),min,104.42,59079,DB00320,Dihydroergotamine
,7368942,plasma clearance,"and 115.79 min., and the mean plasma clearance value 202.88 ml/min.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),[ml] / [min],202.88,59080,DB00320,Dihydroergotamine
,7368942,Vdc,"Similarly, the Vdc - values were 0.121/kg and significantly from each other.",The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7368942/),1/[kg],0.121,59081,DB00320,Dihydroergotamine
,18179563,t(max),Post-peak (t(max) approximately 12 minutes) DHE concentrations achieved after 4 actuations ( approximately 0.88 mg respirable dose) of MAP0004 were comparable to those detected after IV administration.,Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179563/),min,12,62460,DB00320,Dihydroergotamine
,354304,alpha-phase half-life,"Dihydroergotamine disappeared quickly from plasma, with a mean alpha-phase half-life of 1.35 min, which explained its rapid effect on blood pressure.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),min,1.35,68156,DB00320,Dihydroergotamine
,354304,Beta-phase half-life,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),min,23.20,68157,DB00320,Dihydroergotamine
,354304,volume of distribution at beta-phase,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),[i] / [kg],0.25,68158,DB00320,Dihydroergotamine
,354304,total plasma clearance,"Beta-phase half-life (mean 23.20 min), the volume of distribution at beta-phase (mean 0.25 I/kg), and the total plasma clearance (mean 1562.8 ml/min) indicate rapid elimination of the drug from the body.",Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/354304/),[ml] / [min],1562.8,68159,DB00320,Dihydroergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2857,72673,DB00320,Dihydroergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2624,72674,DB00320,Dihydroergotamine
,23926420,AUC(0-2h),"The change in PASP with IV DHE was significantly different than MAP0004 and placebo (AUC(0-2h)2857, 2624, and 2453 mmHg*min, respectively).",Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23926420/),min·mmhg,2453,72675,DB00320,Dihydroergotamine
,3988387,peak plasma concentrations,The drug was rapidly absorbed from the injection site; peak plasma concentrations of 3-8 ng/ml were observed within 15-45 min of dosing.,Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ng] / [ml],3-8,82128,DB00320,Dihydroergotamine
,3988387,Half-lives,"Half-lives for the rapid and slow phases of decline in plasma dihydroergotamine were 0.95 and 7.26 h, respectively.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),h,0.95,82129,DB00320,Dihydroergotamine
,3988387,Half-lives,"Half-lives for the rapid and slow phases of decline in plasma dihydroergotamine were 0.95 and 7.26 h, respectively.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),h,7.26,82130,DB00320,Dihydroergotamine
,3988387,overall volume of distribution,The overall volume of distribution was 14.6 l/kg.,Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[l] / [kg],14.6,82131,DB00320,Dihydroergotamine
,3988387,plasma clearance,"The plasma clearance and renal clearance values were 1814 and 91 ml/min, respectively, indicating that 5% of the dose was excreted unchanged in the urine.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ml] / [min],1814,82132,DB00320,Dihydroergotamine
,3988387,renal clearance,"The plasma clearance and renal clearance values were 1814 and 91 ml/min, respectively, indicating that 5% of the dose was excreted unchanged in the urine.",Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988387/),[ml] / [min],91,82133,DB00320,Dihydroergotamine
,649230,alpha-phase half-life,"After single 0.5-mg nad 1.0-mg i.v. injections, dihydroergotamine, as measured by a radioimmunoassay, disappeared quickly from the plasma of beagles, with a mean alpha-phase half-life of 1.32--1.91 min.",The pharmacokinetics of dihydroergotamine in the beagle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,1.32,88124,DB00320,Dihydroergotamine
,649230,beta-phase half-life,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,40.79,88125,DB00320,Dihydroergotamine
,649230,volume of ditribution at beta-phase,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[l] / [kg],1.50,88126,DB00320,Dihydroergotamine
,649230,plasma clearance,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[ml] / [min],311.67,88127,DB00320,Dihydroergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.7,88128,DB00320,Dihydroergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.3,88129,DB00320,Dihydroergotamine
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,3.1,88130,DB00320,Dihydroergotamine
,8841149,peak plasma levels,"Nasally administered dihydroergotamine (1 mg) becomes rapidly available to the systemic circulation, with peak plasma levels of 1 ng/ml achieved in 0.9 hour.",Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),[ng] / [ml],1,88362,DB00320,Dihydroergotamine
,8841149,relative bioavailability,The relative bioavailability versus intramuscular route is 38.4%.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,38.4,88363,DB00320,Dihydroergotamine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,29,88364,DB00320,Dihydroergotamine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,20,88365,DB00320,Dihydroergotamine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,25,88366,DB00320,Dihydroergotamine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,14,88367,DB00320,Dihydroergotamine
,3101710,bioavailability,The bioavailability of G-1-N in the rat and in the dog is practically 100%.,"[Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3101710/),%,100,107989,DB00320,Dihydroergotamine
,29051065,area under curve (AUC),"The area under curve (AUC) value after DHE delivery by MNP (1259±917ng/mL min) was not significantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability of 97%.",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),[ng] / [min·ml],1259,132466,DB00320,Dihydroergotamine
,29051065,relative bioavailability,"The area under curve (AUC) value after DHE delivery by MNP (1259±917ng/mL min) was not significantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability of 97%.",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),%,97,132467,DB00320,Dihydroergotamine
,29051065,tmax,"Also, appreciable plasma levels of DHE were seen within 5min for both delivery methods and tmax value of MNPs (38±23min) showed no significant difference (p>0.05) compared to subcutaneous injection (24±13min).",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),min,38,132468,DB00320,Dihydroergotamine
,29051065,tmax,"Also, appreciable plasma levels of DHE were seen within 5min for both delivery methods and tmax value of MNPs (38±23min) showed no significant difference (p>0.05) compared to subcutaneous injection (24±13min).",Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051065/),min,24,132469,DB00320,Dihydroergotamine
,7228454,T 1/2 beta,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),min,32.9,134934,DB00320,Dihydroergotamine
,7228454,Vdss,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[l] / [kg],0.33,134935,DB00320,Dihydroergotamine
,7228454,Cltot,"After a single 1.0 mg intravenous injection (n = 5) DHE quickly disappeared (T 1/2 beta = 32.9 min, Vdss = 0.33 liter/kg, Cltot = 1055.7 ml/min).",Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],1055.7,134936,DB00320,Dihydroergotamine
,7228454,cumulative urinary excretion,The 32-h cumulative urinary excretion was 0.02-0.04% of the 1.0 mg intravenous dose.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),h,32,134937,DB00320,Dihydroergotamine
,7228454,cumulative urinary excretion,The 32-h cumulative urinary excretion was 0.02-0.04% of the 1.0 mg intravenous dose.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),%,0.02-0.04,134938,DB00320,Dihydroergotamine
,7228454,renal,In one subject renal (0.18 ml/min) and extrarenal (692.9 ml/min) clearance of DHE was calculated.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],0.18,134939,DB00320,Dihydroergotamine
,7228454,extrarenal,In one subject renal (0.18 ml/min) and extrarenal (692.9 ml/min) clearance of DHE was calculated.,Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7228454/),[ml] / [min],692.9,134940,DB00320,Dihydroergotamine
,7093108,apparent half-time of elimination,The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min.,Bioavailability of dihydroergotamine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),h,2.37,151512,DB00320,Dihydroergotamine
,7093108,plasma clearance,The mean apparent half-time of elimination was 2.37 +/- 0.29 h and plasma clearance of dHE was 1002 +/- 169 ml/min.,Bioavailability of dihydroergotamine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),[ml] / [min],1002,151513,DB00320,Dihydroergotamine
,7093108,apparent absorption,3 Mean apparent absorption of DHE determined from the 10 mg dose was 26.6 +/- 10% and ranged from 8.9 to 60.3%.,Bioavailability of dihydroergotamine in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,26.6,151514,DB00320,Dihydroergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.47,151515,DB00320,Dihydroergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.59,151516,DB00320,Dihydroergotamine
,7093108,oral bioavailability,"The oral bioavailability after the 10, 20 and 30 mg doses averaged 0.47 +/- 0.07%, 0.59 +/- 0.13% and 0.52 +/- 0.14% respectively.",Bioavailability of dihydroergotamine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093108/),%,0.52,151517,DB00320,Dihydroergotamine
,31985049,Cmax,"In part 1, DHE plasma levels showed a dose-dependent increase, with STS101 5.2 mg reaching a mean Cmax of 1870 pg/mL with a Tmax of 23 minutes.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1870,154039,DB00320,Dihydroergotamine
,31985049,Tmax,"In part 1, DHE plasma levels showed a dose-dependent increase, with STS101 5.2 mg reaching a mean Cmax of 1870 pg/mL with a Tmax of 23 minutes.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),min,23,154040,DB00320,Dihydroergotamine
,31985049,plasma concentrations,"In part 2, STS101 5.2 mg showed rapid absorption, achieving mean DHE plasma concentrations of 1230 and 1850 pg/mL at 10 and 15 minutes after administration, respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1230,154041,DB00320,Dihydroergotamine
,31985049,plasma concentrations,"In part 2, STS101 5.2 mg showed rapid absorption, achieving mean DHE plasma concentrations of 1230 and 1850 pg/mL at 10 and 15 minutes after administration, respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],1850,154042,DB00320,Dihydroergotamine
,31985049,Cmax,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],2175,154043,DB00320,Dihydroergotamine
,31985049,Cmax,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[pg] / [ml],961,154044,DB00320,Dihydroergotamine
,31985049,AUC0-2 h,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],2979,154045,DB00320,Dihydroergotamine
,31985049,AUC0-2 h,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],1316,154046,DB00320,Dihydroergotamine
,31985049,AUC0-inf,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"12,030",154047,DB00320,Dihydroergotamine
,31985049,AUC0-inf,"In comparison to Migranal, STS101 5.2 mg showed approximately 2-fold higher Cmax (2175 vs 961 pg/mL), AUC0-2 h (2979 vs 1316 h × pg/mL), and AUC0-inf (12,030 vs 6498 h × pg/mL), respectively.","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],6498,154048,DB00320,Dihydroergotamine
,31985049,AUC0-inf,"The mean AUC0-inf of STS101 5.2 mg was comparable to IM DHE (12,030 vs 13,650 h × pg/mL).","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"12,030",154049,DB00320,Dihydroergotamine
,31985049,AUC0-inf,"The mean AUC0-inf of STS101 5.2 mg was comparable to IM DHE (12,030 vs 13,650 h × pg/mL).","A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31985049/),[h·pg] / [ml],"13,650",154050,DB00320,Dihydroergotamine
,6428916,alpha-,"The plasma level of non-volatile radioactivity declined biphasically with alpha- and beta-phase half-lives of 2.1 h and 32.3 h, respectively.","Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428916/),h,2.1,187423,DB00320,Dihydroergotamine
,6428916,beta-phase half-lives,"The plasma level of non-volatile radioactivity declined biphasically with alpha- and beta-phase half-lives of 2.1 h and 32.3 h, respectively.","Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428916/),h,32.3,187424,DB00320,Dihydroergotamine
,9872338,brain-to-plasma concentration ratio,"Following an i.v. dose, DHE distributed into the brain with a brain-to-plasma concentration ratio of approximately 5% at 30 min postdose.",Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),%,5,195298,DB00320,Dihydroergotamine
,9872338,PeA,The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions.,Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),[ml] / [g·min],8.6 x 10(-4),195299,DB00320,Dihydroergotamine
,9872338,PeA,The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions.,Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872338/),[ml] / [g·min],37.5 x 10(-4),195300,DB00320,Dihydroergotamine
,6126364,bioavailability,In six volunteers bioavailability was reduced to 35% for a fast release tablet and to 17% for a sustained release preparation.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,35,204021,DB00320,Dihydroergotamine
,6126364,bioavailability,In six volunteers bioavailability was reduced to 35% for a fast release tablet and to 17% for a sustained release preparation.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,17,204022,DB00320,Dihydroergotamine
,6126364,bioavailability,The addition of dihydroergotamine (DHE) to the sustained release preparation surprisingly increased bioavailability to 61%.,Dihydroergotamine increases the bioavailability of orally administered etilefrine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126364/),%,61,204023,DB00320,Dihydroergotamine
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,2.13,208818,DB00320,Dihydroergotamine
,7245123,halflife,The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (P less than 0.02).,Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7245123/),h,1.36,208819,DB00320,Dihydroergotamine
,6612697,peak plasma levels,"Subcutaneously administered dihydroergotamine (DHE) becomes rapidly and completely available to the human systemic circulation, with peak plasma levels of 1.4-3.5 ng/mL/mg achieved in less than 1 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[ng] / [mg·ml],1.4-3.5,212053,DB00320,Dihydroergotamine
,6612697,t 1/2 alpha,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,1,212054,DB00320,Dihydroergotamine
,6612697,t 1/2 beta,"The elimination of DHE from plasma is biphasic, t 1/2 alpha = 1h, t 1/2 beta = 4-5 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),h,4-5,212055,DB00320,Dihydroergotamine
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.3,212056,DB00320,Dihydroergotamine
,6612697,peak plasma levels,"Heparin peak plasma levels (0.3 I.U./mL by activated factor X, 0.1 I.U./mL by protamine titration with a 15,000 I.U. s.c. bolus) are achieved in 3.6 h.","The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6612697/),[i·u] / [ml],0.1,212057,DB00320,Dihydroergotamine
,11888055,overall extraction recoveries,"The overall extraction recoveries of DHE and 8'-OH-DHE were determined to be about 58 and 52% on average, respectively.",Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),%,58,223250,DB00320,Dihydroergotamine
,11888055,overall extraction recoveries,"The overall extraction recoveries of DHE and 8'-OH-DHE were determined to be about 58 and 52% on average, respectively.",Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),%,52,223251,DB00320,Dihydroergotamine
,11888055,ch,The chromatographic run time was approximately 2.5 min.,Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),min,2.5,223252,DB00320,Dihydroergotamine
,11888055,run time,The chromatographic run time was approximately 2.5 min.,Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888055/),min,2.5,223253,DB00320,Dihydroergotamine
,6685489,bioavailability,The bioavailability of IS-2-MN in the rat was 100%.,"[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685489/),%,100,234412,DB00320,Dihydroergotamine
,11453889,DeltaAUC,"Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively.","Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h·mm,-8.81,243831,DB00320,Dihydroergotamine
,11453889,DeltaAUC,"Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively.","Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),[h] / [kpa],-0.98,243832,DB00320,Dihydroergotamine
,11453889,Time to reach maximum plasma concentration,Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h.,"Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h,0.33,243833,DB00320,Dihydroergotamine
,11453889,terminal half-life,Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h.,"Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453889/),h,5.63,243834,DB00320,Dihydroergotamine
,6794970,plasma half-life,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),h,2.15,249571,DB00320,Dihydroergotamine
,6794970,plasma clearance,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ml] / [min],862,249572,DB00320,Dihydroergotamine
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],0,249573,DB00320,Dihydroergotamine
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],2,249574,DB00320,Dihydroergotamine
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,19.5,249575,DB00320,Dihydroergotamine
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,53.3,249576,DB00320,Dihydroergotamine
less,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249577,DB00320,Dihydroergotamine
,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249578,DB00320,Dihydroergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,56,249579,DB00320,Dihydroergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,370,249580,DB00320,Dihydroergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249581,DB00320,Dihydroergotamine
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249582,DB00320,Dihydroergotamine
,7870666,Absolute bioavailability,"Absolute bioavailability of the parent drug was 35%-40%, as determined by deconvolution and by the ratios of AUC0-infinity following intranasal and intravenous dosing.",Pharmacokinetics of intranasally-administered dihydroergotamine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870666/),%,35%-40,255453,DB00320,Dihydroergotamine
,1815973,half-life,A long terminal plasma elimination phase of unchanged DHE (half-life 15 h) was found.,Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),h,15,261324,DB00320,Dihydroergotamine
,1815973,Plasma protein binding,Plasma protein binding was 93%.,Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),%,93,261325,DB00320,Dihydroergotamine
,1815973,tissue distribution (Vz,"Despite extensive tissue distribution (Vz = 33 l/kg) and a high plasma clearance (CLP = 2 l/min), dose-independent linear pharmacokinetics was observed.",Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),[l] / [kg],33,261326,DB00320,Dihydroergotamine
,1815973,plasma clearance (CLP,"Despite extensive tissue distribution (Vz = 33 l/kg) and a high plasma clearance (CLP = 2 l/min), dose-independent linear pharmacokinetics was observed.",Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815973/),[l] / [min],2,261327,DB00320,Dihydroergotamine
,6192998,t0.5 alpha,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,1.4,270075,DB00320,Dihydroergotamine
,6192998,t0.5 alpha,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,2.0,270076,DB00320,Dihydroergotamine
,6192998,t0.5 beta,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,22,270077,DB00320,Dihydroergotamine
,6192998,t0.5 beta,"DHE was rapid and the disappearance curve followed a biphasic pattern, t0.5 alpha being 1.4 and 2.0 h, t0.5 beta 22 and 21 h for DHE and DHE/dextran 70, respectively.",The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),h,21,270078,DB00320,Dihydroergotamine
,6192998,trough levels,DHE trough levels were about 0.5 ng/ml and were well above the assumed minimum effective value to induce venoconstriction (0.06 ng/ml).,The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),[ng] / [ml],0.5,270079,DB00320,Dihydroergotamine
,6192998,minimum effective,DHE trough levels were about 0.5 ng/ml and were well above the assumed minimum effective value to induce venoconstriction (0.06 ng/ml).,The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6192998/),[ng] / [ml],0.06,270080,DB00320,Dihydroergotamine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,118,273139,DB00320,Dihydroergotamine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,310,273140,DB00320,Dihydroergotamine
